Recent Updates
Recently added Catalysts
BBNX Positive Sentiment Score: 75/100

Beta Bionics to Host Investor Event on June 22, 2025

Wednesday, April 9, 2025 2 min read
Key Takeaway: Beta Bionics, Inc. announced it will host an investor event on June 22, 2025, coinciding with the American Diabetes Association's 85th Scientific Sessions in Chicago. The event will feature presentations from the management team, including updates on financial performance and a demonstration of the patch pump under development. Investors can attend in person or via a live webcast, with a replay available afterwards. The company continues to innovate in diabetes management solutions, notably with its FDA-cleared iLet Bionic Pancreas.

Market Sentiment Analysis

POSITIVE FACTORS

  • Beta Bionics is hosting an investor event to showcase its innovations.
  • The event will provide updates on commercial and financial performance.
  • A demonstration of a new patch pump in development will be presented.
  • New real-world clinical data will be shared with investors.

Full Press Release Details

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time).
Members of the Company’s management team, led by Sean Saint, President and CEO, will present at the event. The agenda will include updates on commercial and financial performance, a demonstration of the patch pump in development, a review of the adaptive closed-loop algorithm, and new real-world clinical data.
The Company invites investors to join the event via live webcast, a link to which will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com. Following the event, a replay of the webcast and its accompanying slide presentation will be archived on the Company’s website.
Investors who would like to attend the event in-person will be required to register, which can be done by contacting the Company’s investor relations representative at ir@betabionics.com.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Head of Investor Relations
Media and Public Relations:
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.

Frequently Asked Questions

When is Beta Bionics' investor event?

The investor event is on June 22, 2025, starting at 7:00 am Central Time.

How can investors attend the investor event?

Investors can attend via a live webcast or in-person by registering with investor relations.

What will be discussed at the investor event?

The event will cover commercial performance, the patch pump demonstration, and new clinical data.

What is the iLet Bionic Pancreas?

The iLet Bionic Pancreas is an FDA-cleared device that autonomously delivers insulin.

Where can I find more information on Beta Bionics?

More information is available on Beta Bionics’ website at www.betabionics.com.

Tags: BBNX Viatris Investor Conferences Healthcare Beta Bionics diabetes management investor event iLet Bionic Pancreas ADA Scientific Sessions
Last updated: Apr 9, 2025